drugset / Trial / NCT07345000

A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia

NCT07345000

Phase 3 Not yet recruiting 210 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, multicenter trial designed to evaluate treatment with romiplostim N01+ IST compared with placebo + IST in the participants with treatment-naïve severe aplastic anemia.

Timeline

Start
2026-01
Primary completion
2029-10
Completion
2030-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Romiplostim N01 Peptide 10 ug/kg
Comparator Cyclosporine Peptide 5 mg/kg Oral
Comparator anti-human T lymphocyte porcine immunoglobulin Protein / enzyme biologic 25 mg/kg
Comparator rATG Unknown 25 mg/kg
Comparator rATG Unknown 25 mg/kg